MJacob Bliberg (jb3975@stern.nyu.edu) Jasper Buntinx (jasper@buntinx.eu) April 2013 Post-Acquisition Report Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) $6.8Bn acquisition of Cephalon‚ Inc. (NASDAQ: CEPH) – October 14‚ 2011 | Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company which develops‚ produces and markets affordable generic drugs. Teva is the world’s largest generic drug maker‚ with a direct presence in about 60 countries. Teva’s
Premium Generic drug Takeover Pharmaceutical industry
Issues: » Study the synergies of the merger between Hindalco and Novelis » Study the rationale behind Hindalco acquiring a loss making aluminum company » Examine the way the acquisition deal was financed » Analyze whether the deal was overvalued or not » Analyze the trends in the global aluminum industry Keywords: Hindalco Industries Limited‚ Novelis Inc.‚ Merger and Acquisition‚ Deal Valuation‚ Debt-equity Ratio‚ EV/EBITDA Ratio‚ Indian Aluminum Industry‚ Merger Integration‚ Consolidation‚ Downstream
Premium Aditya Birla Group Birla family Kumar Mangalam Birla
To: Professor Susan Patrick From: Virginia M Garman Date: March 4‚ 2013 Re: Memorandum of Law; Rough Draft QUESTION PRESENTED You asked me to answer the question‚ “Are the Virginia courts likely to follow the unconscionability doctrine as set out and applied in Jones v. Star Credit Corp."‚ based on the opinion and rulings of previous similar cases. SHORT ANSWER The Virginia courts are highly likely to follow the unconscionability doctrine that has been set out and applied in Jones v. Star
Premium Contract Marriage
INTEROFFICE MEMORANDUM |TO: |Morgan Burkhart‚ Senior Partner | |FROM: |Heidi Selman‚ Paralegal Student | |DATE: |May 8‚ 2013
Premium Tort Property law Swimming pool
GROUP PROJECT IN MERGER‚ ACQUISTION & CORPORATE RESTRUCTURING “HINDALCO’S NOVELIS ACQUISITION” Submitted By: 1) Rakesh Ranjan (PGEXP/2011/19) 2) Subash Ch. Das (PGEXP/2011/56) 3) Kumud Anand (PGEXP/2011/21) 4) Abinash Kumar Sahu (PGEXP/2011/26) 5) Anupam Sinha (PGEXP/2011/53) 6) Rajeev Kumar Gupta (PGEXP/2011/10) ← “If we earn $10 for every $100 of aluminum we sell‚ we will now be able to earn another $10 for every $100 worth of
Premium Aluminium Aditya Birla Group
June 13‚ 2011 TAX FILE MEMORANDUM FROM Lance Vogt SUBJECT Cindy and Ralph Edmonds FACTS Cindy and Ralph Edmonds own TidyCo. Inc. They have a negative accumulated and current E&P and a basis in the stock of $300‚000. They have been found to have $200‚000 unreported income from the Laundromat they own in cash in their home. The IRS is planning on taking them to criminal court to charge them with evasion. ISSUE Does any of the information or facts effect on the evasion charges.
Premium Tax Corporation Service of process
Memorandum To: FutureMed From: Smeed Subject: Project Delta Schedule February 16‚ 2013 CC: Jack Welch The review of scheduling for Project Delta indicates that the deadline of October 25 is unempirical for producing thirty working models. Within this report are two findings for Project Delta’s schedule and the critical path is identified. The findings and recommendations can prove that Project Delta will not only be impossible to complete on time‚ but it will not have any possibility
Premium Project management Management Plan
Signaling and risk allocation in merger agreements Antonio J. Macias* Thomas Moeller** Abstract Acquirers and targets allocate interim risk in merger agreements through Material Adverse Change (MAC) clauses and exclusions. While virtually all acquisitions have MAC clauses‚ there is broad cross-sectional variation in the number and type of MAC exclusions. Using comprehensive hand-collected data‚ we find that acquisitions with fewer firm-specific MAC exclusions‚ i.e.‚ stronger abandonment options
Premium Mergers and acquisitions Information asymmetry
A REPORT ON Ranbaxy-Daiichi Deal 1/26/2012 Ranbaxy-Daiichi Deal Introduction: Daiichi Sankyo bought Ranbaxy for $4.6 billion in June 2008. This report studies the implications of the merger between Ranbaxy and Daiichi Sankyo‚ from an intellectual property as well as a market point of view. There are many critical events happening in international pharma market including the growing preference for generics‚ increasing dominance of emerging markets such as India‚ fast approaching patent expiry
Premium Generic drug Ranbaxy Laboratories Pharmaceutical industry
Probir (2004): The Hewlett Packard- Compaq Computers Merger: Insight from the Resource-Based View and the Dynamic Capabilities Perspective‚ Journal of American Academy of Business‚ Cambridge. Hollywood: Vol. 5‚ Iss. Pgs 7‚8. Freidman J. (1971)‚ “A Non-cooperative Equilibrium for Supergames.” Review of Economic Studies‚ 38‚ 1-12. Stigler‚ G. J. (1964) “A theory of Oligopoly”‚ Journal of Political Economy‚ 72‚ 44-61. Baker‚ J Nevo‚ A. (2000a). "Mergers with Di¤erentiated Products: The Case of the Ready-to-
Premium Hewlett-Packard